Company · Healthtech & Bio

INBRAIN Neuroelectronics

inbrain-neuroelectronics.com ↗ ·Barcelona ·Series B

INBRAIN Neuroelectronics is a Barcelona-based clinical-stage neurotech company developing graphene-based, AI-powered brain-computer interface (BCI) therapeutics to decode and modulate neural activity for treating neurological disorders such as Parkinson's disease and brain tumors. Spun off from ICN2 in 2019, it holds FDA Breakthrough Device Designation and performed the world's first human graphene BCI procedure in 2024. It has raised over $80M to date, most recently a $50M Series B led by imec.xpand, and has a strategic partnership with Merck KGaA.

Founded
2019
Founders
5
News
10
Rounds
5
Investors
14
SectorsBrain-computer interfaces, Neurotech, Medical devices, Bioelectronics, Graphene/nanomaterials Start-up MapHealthtech & Bio › Medical devices & surgical hardware

Profile updated 23 Jul 2026

Founders

Anton Guimerà Brunet
Co-founder & Technology Advisor
Carolina Aguilar
CEO & Co-founder
Jose Antonio Garrido
Co-founder & Chief Scientific Officer
Kostas Kostarelos
Co-founder
Mario Capizzani
Co-founder & Chief Commercial Officer

Global models 5

Neuralink
United States · neuralink.com ↗
Direct global comparable building implantable brain-computer interfaces to decode and modulate neural activity, though focused more on motor/communication restoration than INBRAIN's neurological disease therapeutics.
$1.3BComparable
Synchron
United States · synchron.com ↗
Develops minimally-invasive BCI implants (Stentrode) to decode neural signals for paralysis patients, closely matching INBRAIN's neural-decoding therapeutic BCI model.
$255MComparable
Precision Neuroscience
United States · precisionneuro.io ↗
Builds high-resolution, minimally invasive cortical neural interfaces for brain mapping and BCI applications, similar to INBRAIN's high-resolution graphene electrode approach.
$155MComparable
Paradromics
United States · www.paradromics.com ↗
Develops high-bandwidth implantable neural interfaces for decoding brain activity to treat neurological conditions, a close model match to INBRAIN's BCI-therapeutics platform.
$150MComparable
Blackrock Neurotech
United States · blackrockneuro.com ↗
Long-standing developer of implantable brain-computer interface hardware for neural decoding and neuromodulation therapies, mirroring INBRAIN's clinical BCI focus.
$90MComparable

Investors 14

Aliath Bioventures
Investor Spain
Alta Life Sciences
altals.com
Investor Spain
Asabys Partners
asabys.com
Investor Spain
Investor Spain
Axis Participaciones Empresariales
axispart.com
Investor Spain
CDTI Innvierte
www.cdti.es
Investor Spain
Earthshots Collective
Investor
EIC Fund
eic.ec.europa.eu
Investor Luxembourg
Investor Spain
Investor Belgium
Investor France
TruVenturo
Investor Germany
Vsquared Ventures
Investor Germany
Wellington Partners
Investor Germany

Funding rounds 5

Other · €3M
Avançsa, the Catalan government's industrial promotion company, entered the capital of graphene brain-computer-interface developer INBRAIN N…
2024-11-26
Series B · $50M
Barcelona-based INBRAIN Neuroelectronics, an ICN2/CSIC spin-off developing graphene-based brain-computer interfaces for neurological conditi…
2024-10-29
Debt · €20M
The ICN2/ICREA spin-off, which develops graphene-based neural interfaces for Parkinson's, epilepsy and speech disorders, closed a €20M ventu…
2023-12-13
Other · €17.5M
INBRAIN develops graphene brain-computer interfaces. It won an EIC Accelerator award of up to €17.5M, made up of a €2.5M grant and up to €15…
2022-12-19
Seed · €100K
Banco Sabadell's BStartup Health programme invested €100K in INBRAIN Neuroelectronics, a spin-off of the Catalan Institute of Nanoscience an…
2020-11-03

News & media 10

Start typing to search across everything.
↑↓ navigate↵ openesc close